Author:
Ifversen Marianne,Meisel Roland,Sedlacek Petr,Kalwak Krzysztof,Sisinni Luisa,Hutt Daphna,Lehrnbecher Thomas,Balduzzi Adriana,Diesch Tamara,Jarisch Andrea,Güngör Tayfun,Stein Jerry,Yaniv Isaac,Bonig Halvard,Kuhlen Michaela,Ansari Marc,Nava Tiago,Dalle Jean-Hugues,Diaz-de-Heredia Cristina,Trigoso Eugenia,Falkenberg Ulrike,Hartmann Mihaela,Deiana Marco,Canesi Marta,Broggi Chiara,Bertaina Alice,Gibson Brenda,Krivan Gergely,Vettenranta Kim,Matic Toni,Buechner Jochen,Lawitschka Anita,Peters Christina,Yesilipek Akif,Yalçin Koray,Lucchini Giovanna,Bakhtiar Shahrzad,Turkiewicz Dominik,Niinimäki Riitta,Wachowiak Jacek,Cesaro Simone,Dalissier Arnaud,Corbacioglu Selim,Willasch Andre Manfred,Bader Peter
Abstract
Specific protocols define eligibility, conditioning, donor selection, graft composition and prophylaxis of graft vs. host disease for children and young adults undergoing hematopoietic stem cell transplant (HSCT). However, international protocols rarely, if ever, detail supportive care, including pharmaceutical infection prophylaxis, physical protection with face masks and cohort isolation or food restrictions. Supportive care suffers from a lack of scientific evidence and implementation of practices in the transplant centers brings extensive restrictions to the child's and family's daily life after HSCT. Therefore, the Board of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT) held a series of dedicated workshops since 2017 with the aim of initiating the production of a set of minimal recommendations. The present paper describes the consensus reached within the field of infection prophylaxis.
Subject
Pediatrics, Perinatology, and Child Health